{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:53:04Z","timestamp":1761598384011,"version":"3.41.2"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Fingolimod (FTY) is a disease modifying therapy for relapsing remitting multiple sclerosis (RRMS) which can lead to severe lymphopenia requiring therapy discontinuation in order to avoid adverse events. However, this can result in severe disease reactivation occasionally presenting with tumefactive demyelinating lesions (TDLs). TDLs, which are thought to originate from a massive re-entry of activated lymphocytes into the central nervous system, are larger than 2 cm in diameter and may feature mass effect, perifocal edema, and gadolinium enhancement. In these cases, it can be challenging to exclude important differential diagnoses for TDLs such as progressive multifocal leukoencephalopathy (PML) or other opportunistic infections. Here, we present the case of a 26-year-old female patient who suffered a massive rebound with TDLs following FTY discontinuation with primarily neuropsychiatric symptoms despite persisting lymphopenia. Two cycles of seven plasmaphereses each were necessary to achieve remission and ocrelizumab was used for long-term stabilization.<\/jats:p>","DOI":"10.3389\/fneur.2021.785180","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T05:13:20Z","timestamp":1635484400000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal"],"prefix":"10.3389","volume":"12","author":[{"given":"Valeria","family":"Koska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"F\u00f6rster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Brouzou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ercan","family":"Arat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"K\u00fcry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","article-title":"Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population","volume":"34","author":"Boffa","year":"2020","journal-title":"CNS Drugs."},{"key":"B2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40261-019-00804-6","article-title":"Severe exacerbation of multiple sclerosis following withdrawal of fingolimod","volume":"39","author":"Fragoso","year":"2019","journal-title":"Clin Drug Investig."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101883","DOI":"10.1016\/j.msard.2019.101883","article-title":"Tumefactive rebound of multiple sclerosis after the short-term cessation of fingolimod: a case report","volume":"39","author":"Ashtari","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/jnnp-2012-304498","article-title":"Tumefactive demyelination: an approach to diagnosis and management","volume":"84","author":"Hardy","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1177\/1352458512463768","article-title":"Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod","volume":"18","author":"Jander","year":"2012","journal-title":"Mult Scler."},{"key":"B6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cellsig.2004.08.006","article-title":"In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights","volume":"17","author":"McVerry","year":"2005","journal-title":"Cell Signal."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2055217317730096","DOI":"10.1177\/2055217317730096","article-title":"A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo","volume":"3","author":"Vermersch","year":"2017","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.2169\/internalmedicine.0793-18","article-title":"Disease exacerbation after the cessation of fingolimod treatment in Japanese patients with multiple sclerosis","volume":"57","author":"Sato","year":"2018","journal-title":"Intern Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1001\/archneurol.2011.1057","article-title":"Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment","volume":"69","author":"Havla","year":"2012","journal-title":"Arch Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbi.2015.06.019","article-title":"Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound","volume":"50","author":"Cavone","year":"2015","journal-title":"Brain Behav Immun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2055217318759692","DOI":"10.1177\/2055217318759692","article-title":"Risk factors for fingolimod-induced lymphopenia in multiple sclerosis","volume":"4","author":"Ohtani","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1177\/1352458518763095","article-title":"Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation","volume":"24","author":"Giordana","year":"2018","journal-title":"Mult Scler."},{"key":"B13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jneuroim.2015.03.022","article-title":"Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation","volume":"282","author":"Berger","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"103076","DOI":"10.1016\/j.msard.2021.103076","article-title":"How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP)","volume":"53","author":"Bigaut","year":"2021","journal-title":"Mult Scler Relat Disord."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.785180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T05:13:22Z","timestamp":1635484402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.785180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":14,"alternative-id":["10.3389\/fneur.2021.785180"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.785180","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"article-number":"785180"}}